Crossmark

A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk

Crossref DOI link: https://doi.org/10.1007/s12328-020-01093-9

Published Online: 2020-01-23

Published Print: 2020-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kosaka, Yumi

Kawaoka, Tomokazu

Aikata, Hiroshi https://orcid.org/0000-0002-3409-2156
Suehiro, Yosuke

Yamaoka, Kenji

Ando, Yuwa

Namba, Maiko

Takeuchi, Yasue

Fujii, Yasutomo

Uchikawa, Shinsuke

Kodama, Kenichiro

Oya, Kazuki

Morio, Kei

Fujino, Hatsue

Nakahara, Takashi

Murakami, Eisuke

Yamauchi, Masami

Tsuge, Masataka

Hiramatsu, Akira

Imamura, Michio

Baba, Yasutaka

Awai, Kazuo

Kimura, Tomoki

Nagata, Yasushi

Chayama, Kazuaki
License Information

Text and Data Mining valid from 2020-01-23

Version of Record valid from 2020-01-23
More Information

Article History

Received: 14 August 2019

Accepted: 14 January 2020

First Online: 23 January 2020

Compliance with ethical standards

:

: Kazuaki Chayama has received honoraria from Bristol-Myers Squibb, MSD K.K., AbbVie Inc., Gilead Sciences, Dainippon Sumitomo Pharma and Mitsubishi Tanabe and research funding from Dainippon Sumitomo Pharma, MSD K.K, AbbVie Inc, Eisai, Toray, Otsuka, Chugai, Takeda, Roche, Mitsubishi Tanabe and Bristol-Byers Squibb. Michio Imamura has received research funding from Bristol-Myers Squibb. Other authors declare no competing interests.

: All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all patients for being included in the study.

Document is current

Any future updates will be listed below